Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two-Year Ban On Device Tax Approved In Tax-Extenders Bill

This article was originally published in The Gray Sheet

Executive Summary

Congress passed a two-year moratorium on the 2.3% device excise tax as part of a tax-extenders package, Dec. 18, and President Obama was expected to sign it. The legislation also includes a permanent extension of the research & development tax credit.

You may also be interested in...



Medtech's Unfinished Business For Congress In 2018: What's Ahead

US Congress successfully pushed through a user-fee bill in 2017 to help smooth the regulatory path at FDA for medical devices and other products, but other efforts, including several industry priorities, remain undone. On top on the list, of course, is the effort to repeal the device excise tax. But legislation is also on the table to address diagnostics regulation, telehealth reimbursement, and medtech cybersecurity vulnerability, among other issues. Here is a look at the medtech landscape in Congress in 2018.

Rep. Paulsen Re-Introduces Bill To Repeal Device Tax

The Minnesota congressman is taking another stab at chopping off the 2.3 medical device excise tax as part of the wider Obamacare repeal actions anticipated for the new Congress.

Stakeholders Must ‘Fully Engage’ If WHO’s Medicines Access Platform Is To Succeed

Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel